WO2000050013A1 - Rapidly-soluble compositions - Google Patents
Rapidly-soluble compositions Download PDFInfo
- Publication number
- WO2000050013A1 WO2000050013A1 PCT/GB2000/000630 GB0000630W WO0050013A1 WO 2000050013 A1 WO2000050013 A1 WO 2000050013A1 GB 0000630 W GB0000630 W GB 0000630W WO 0050013 A1 WO0050013 A1 WO 0050013A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- carbohydrate polymer
- rapidly
- tablets
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Definitions
- the present invention relates to rapidly-soluble compositions.
- the compositions are suitable for use as vehicles for the delivery, e.g. the mucosal or oral delivery, of bioactive substances.
- the compositions are also suitable for use as delivery vehicles for active substances requiring rapid release.
- Background of the Invention The most common pharmaceutical dosage form is the tablet.
- the main limitations of tablets are poor patient compliance due to the difficulty in swallowing tablets and the difficulty in achieving effective dissolution, to release the bioactive contents.
- a number of approaches have been used, including effervescent tablets using a variety of volatile material-generating systems, chewable tablets, disintegrants and wic ing agents.
- compositions have been formulated using rapidly-soluble matrices. These are especially useful for oral administration, such as for the lingual, sublingual or buccal delivery of drugs.
- rapidly-soluble solid dosage forms are made by aliquoting a slurry of therapeutic agent, solvent, gelatin and other excipients into preformed depressions. The liquid is then frozen and the solvent removed by sublimation, typically freeze-drying. The resulting tablet has an open porous matrix that dissolves rapidly on contact with saliva at body temperature in the mouth.
- This dosage form marketed by R.P.Scherer as Zydis®, has enjoyed commercial success, for instance, as in the Feldene Melt® tablets distributed by Pfizer.
- This type of delivery vehicle allows rapid dissolution of the delivery vehicle on exposure to moisture. Consequently, the tablet dissolves almost immediately upon contact with mucosal surfaces.
- this format enjoys a large market, it has the drawback of containing gelatin.
- Gelatin has the potential of contamination and is unsuitable for the treatment of vegetarians.
- the hygroscopicity of this gelatin formulation also means that Zydis® tablets have to be stored in moisture-resistant packs. The tablets quickly give rise to an unacceptable "sticky" mouth-feel resulting from the poor solubility of gelatin below 37°C, and accentuated by moisture uptake of the freeze-dried gelatin. Following buccal delivery, the mouth should not be washed out for 3-5 minutes.
- EP-A-0357665 and US-A-4855326 describe therapeutic vehicles made from cotton candy. These have the advantages, of cost and simpler, more flexible processing, over Zydis® tablets. However, there are significant problems with the development of validated methods of compacting the candy floss into tablets and with the hygroscopicity of the tablets formed. Further, the tablets exhibit much slower dissolution than Zydis®, which precludes their use in buccal delivery formats which are possible with the latter.
- US-A-4623394 discloses compressed tablets comprising pullulan and a gum-like heteromannan. The intention is to provide gradual disintegration. Even in a control experiment, without the heteromannan, the compressed tablet took over 2 hours to achieve 100% release. Summary of the Invention
- the present invention is based on the surprising discovery that pullulan or HES (hydroxyethyl starch) can satisfactorily be used as a replacement for gelatin, in tablets of the Zydis® type. This is despite the fact that attempts to use most carbohydrates and carbohydrate polymers, to form such matrices, including those proposed as potential substitutes for gelatin in the prior art, did not result in the production of tablets that were comparable to Zydis®.
- Pullulan (which is described herein by way of example only) provided instantaneous dissolution and stablility at ambient temperatures and humidities, thus enabling its use in solid delivery forms as well as reducing the requirements and costs for water-resistant packaging for such delivery forms.
- a rapidly soluble, open matrix of a carbohydrate polymer can be formed by removal of solvent from a solution containing the carbohydrate polymer and any other component(s) , the solution being provided as a single dosage aliquot in a mould corresponding to the desired shape. It appears that materials such as pullulan can readily provide a shaped body that is not only readily invaded by water, but also low friability. Description of the Invention
- the present invention encompasses methods of making rapidly-soluble matrices of sugar (of which pullulan is an example, used herein for illustration) capable of dissolution in minimal volumes of aqueous solvent and of sufficient structural integrity to be handled as discrete units containing actives.
- These products are suitable for use in any applications that require fast-dissolving solid formulations. They are particularly suitable for use in mucosal delivery formulations, such as tablets for per-oral delivery, that dissolve in saliva.
- pullulan, any necessary or desirable excipients and active agent to be delivered are mixed in a liquid (in which one or more of the components may be soluble) , frozen, e.g. in individual dosage aliquots, and then lyophilised, to remove the solvent and yield a rapidly-soluble matrix containing the active.
- a liquid in which one or more of the components may be soluble
- the water or other solvent may also be removed by sublimation or evaporation.
- the liquid may be frozen as part of a continuous process of lyophilisation.
- Products of the invention comprise matrices that are soluble not just at body temperatures but also at ambient and lower temperatures. They are thus suitable not just for oral or buccal delivery as solid matrices but also as soluble matrices for rapid dissolution in aqueous solvent prior to administration.
- the latter formulations may be combined with other excipients and formulations that aid rapid disintegration and dissolution of solid matrices including effervescent couples.
- a wide variety of bioactive materials are suitable for use in accordance with the present invention, including therapeutic and prophylactic agents.
- the delivery vehicle and methods of the present invention provide for a variety of dosing schemes for delivery of the bioactive material and are suitable for both veterinary and human applications.
- any suitable excipient may be used. Many examples will be well known to those skilled in the art. Criteria for the choice of excipients include their effects on the process for obtaining the rapidly-soluble matrix, or the physical or organoleptic characteristics of the matrix.
- the product is a confectionery product and the excipients may include flavoring agents, food dyes, stabilisers and the like.
- the product is a therapeutic composition comprising pharmaceutical excipients as well as biologically active agents such as drugs.
- Excipients suitable for use herein include other carbohydrates including sugars, sugar alcohols, straight- chain polyalcohols and non-reducing glycosides of polyhydroxy compounds.
- the preferred sugar alcohols are mannitol and xylitol.
- the glycosides are preferably monoglycosides, in particular the compounds obtained by reduction of disaccharides such as lactose, maltose, lactulose and maltulose.
- the glycosidic group is preferably a glucoside or a galactoside and the sugar alcohol is preferably sorbitol (glucitol) .
- maltitol (4-O- ⁇ -D-glucopyranosyl-D-glucitol)
- lactitol (4-O- ⁇ -D-galactopyranosyl-D-glucitol)
- iso- maltulose palatinit (a mixture of GPS, ⁇ ⁇ -D-glucopyranosyl-1- 6-sorbitol , and GPM, ⁇ -D-glucopyranosyl-l-6-mannitol)
- palatinit a mixture of GPS, ⁇ ⁇ -D-glucopyranosyl-1- 6-sorbitol , and GPM, ⁇ -D-glucopyranosyl-l-6-mannitol
- GPM ⁇ -D-glucopyranosyl-6-mannitol
- Suitable carbohydrates include, but are not limited to, lactose, , ⁇ , ⁇ and o., ⁇ -trehaloses, raffinose, palatinit, GPS, stachyose, mellibiose and mannotriose.
- the excipients can include those found in confectionaries.
- a low molecular weight carbohydrate e.g. a mono-, di-, tri- or tetrasaccharide
- the amount of therapeutic (or bioactive) agent should be suffficient to yield a final product that contains an effective amount of the therapeutic agent.
- the products obtained are suitable for use as pharmaceuticals, other medical applications such as diagnostics, environmental applications, agricultural and industrial use.
- An effective amount of a bioactive agent is one which causes amelioration or palliation of the condition to be treated.
- bioactive materials examples include any pharmaceutical agents, including anti-inflammatory drugs, analgesics, antiarthritic drugs, antispasmodics, anti-depressants, antipsychotics, tranquilisers, anti-anxiety drugs, narcotic antagonists, anti-Parkinsonism agents, cholinergic agonists, chemotherapeutic drugs, immunosuppressive agents, antiviral agents, antibiotic agents, appetite suppressants, antiemetics, anticholinergics, antihistaminics, anti- migraine agents, coronary, cerebral or peripheral vasodilators, hormonal agents, contraceptives, antithrombotic agents, diuretics, antihypertensive agents, cardiovascular drugs and opioids.
- pharmaceutical agents including anti-inflammatory drugs, analgesics, antiarthritic drugs, antispasmodics, anti-depressants, antipsychotics, tranquilisers, anti-anxiety drugs, narcotic antagonists, anti-Parkinsonism agents, cholinergic agonists, chemotherapeutic drugs, immunos
- Suitable bioactive materials also include biological modifiers.
- Such modifiers include sub ⁇ ellular compositions, cells, bacteria, viruses and molecules including lipids, organics, proteins and peptides (synthetic and natural) , peptide mimetics, hormones (peptide, steroid and corticosteroid) , D and L amino acid polymers, oligosaccharides, polysaccharides , nucleotides, oligonucleotides and nucleic acids, including DNA and RNA, protein-nucleic acid hybrids, small molecules and physiologically active analogues thereof.
- the modifiers may be derived from natural sources or made by recombinant or synthetic means and include analogues, agonists and homologues.
- protein refers also to peptides and polypeptides.
- proteins include enzymes, biopharmaceuticals, growth hormones, growth factors, insulin, monoclonal antibodies, interferons, interleukins and cytokines.
- Organics include pharmaceutically active chemicals with amino, imino and guanidino groups.
- Suitable steroid hormones include estrogen, progesterone, testosterone and physiologically active analogues thereof. Numerous steroid hormone analogues are known in the art and include estradiol, SH-135 and tamoxifen.
- nucleic acids includes any therapeutically effective nucleic acids known in the art including DNA, RNA and physiologically active analogues thereof.
- the nucleotides may encode single genes or may be any vector known in the art of recombinant DNA including plasmids, retroviruses and adeno-associated viruses.
- the nucleotides are administered in the powder form of the solid dose vehicle. Compositions containing prophylactic bioactive materials and carriers therefore are further encompassed by the invention.
- compositions include immunogens such as vaccines.
- Suitable vaccines include live and attenuated viruses, nucleotide vectors encoding antigens, heat-shock protein complexes, bacteria, antigens, antigens plus adjuvants, and haptens coupled to carriers.
- vaccines effective against diphtheria, tetanus, pertussis, botulinum, cholera, Dengue, Hepatitis A, C and E, hemophilus influenza B, herpes virus, Helicobacter pylori , influenza, Japanese encephalitis, meningococci A, B and C, measles, mumps, papilloma virus, pneumococci, polio, rubella, rotavirus, respiratory syncytial virus, Shigella, tuberculosis, yellow fever and combinations thereof.
- Vaccines may also be produced by molecular biology techniques to produce recombinant peptides or fusion proteins containing one or more portions of a protein derived from a pathogen.
- fusion proteins containing the antigen of interest and the B subunit of cholera toxin have been shown to induce an immune response to the antigen of interest. See Sanchez et al (1989), Proc. Natl. Acad. Sci. USA 86:481-485.
- the immunogenic composition contains an amount of an adjuvant sufficient to enhance the immune response to the immunogen.
- Suitable adjuvants include aluminum salts, squalene mixtures (SAF-1) , muramyl peptide, saponin derivatives, mycobacterium cell wall preparations, heat-shock proteins, monophosphoryl lipid A, mycolic acid derivatives, nonionic block copolymer surfactants, Quil A, cholera toxin B subunit, polyphosphazene and derivatives, and immunostimulating complexes (ISCOMs) such as those described by Takahashi et al (1990), Nature 344:873-875.
- itogenic components of Freund's adjuvant can be used.
- the immunologically effective amounts of the immunogens must be determined ertlpirically.
- Factors to be considered include the immunogenicity, whether or not the immunogen will be complexed with or covalently attached to an adjuvant or carrier protein or other carrier, route of administration and the number of immunising doses to be administered. Such factors are known in the vaccine art and it is well within the skill of immunologists to make such determinations without undue experimentation.
- the present invention encompasses compositions and methods of making the compositions. Although singular forms may be used, more than one carbohydrate polymer and more than one excipient and active substance may be present. Determination of the effective amounts of these compounds is within the skill of one in the art.
- Example 1 The exact processing conditions will be depend on the formulation and equipment and can be readily determined by one skilled in the art. Excipients may be added to enhance the processing and/or to tailor the physical or organoleptic properties of the compositions that are obtained. The following Examples illustrate the invention. Example 1
- the solid matrices in the blister packs were of sufficient non- friability (3.52%) to be removed as an intact single dosage unit from the wells of the blister pack and dissolved instantaneously in water ( ⁇ 2sec) at room temperature (15-20°C) , even after a week's storage of the blisters on the bench at ambient temperatures and humidities.
- the friability of commerical Zydis® tablets was 2.8% and the dissolution time c.8 sec.
- the mean water content of the solid matrices was 3.24% (SD 0.19%) and the mean content uniformity of active 98.62% (SD 0.73%).
- Example 2 The procedure of Example 2 was repeated, but using, instead of diltiazem, 20% acyclovir (model hydrophobic active) .
- the solid matrices obtained in the blister packs were of sufficient non-friability (2.69%) to be removed as an intact single dosage unit from the wells and dissolved instantaneously in water ( ⁇ 2sec) at room temperature (15-20°C) , even after a week's storage of the blisters on the bench at ambient temperatures and humidities.
- the mean water content of the solid matrices was 4.75% (0.11%) and the mean content uniformity of active 105.63% (SD 0.96%).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002363126A CA2363126A1 (en) | 1999-02-22 | 2000-02-22 | Rapidly-soluble compositions |
EP00905188A EP1156785A1 (en) | 1999-02-22 | 2000-02-22 | Rapidly-soluble compositions |
AU26815/00A AU2681500A (en) | 1999-02-22 | 2000-02-22 | Rapidly-soluble compositions |
JP2000600625A JP2002537322A (en) | 1999-02-22 | 2000-02-22 | Fast soluble composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9904049.5 | 1999-02-22 | ||
GBGB9904049.5A GB9904049D0 (en) | 1999-02-22 | 1999-02-22 | Rapidly-soluble compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000050013A1 true WO2000050013A1 (en) | 2000-08-31 |
Family
ID=10848274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/000630 WO2000050013A1 (en) | 1999-02-22 | 2000-02-22 | Rapidly-soluble compositions |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1156785A1 (en) |
JP (1) | JP2002537322A (en) |
AU (1) | AU2681500A (en) |
CA (1) | CA2363126A1 (en) |
GB (1) | GB9904049D0 (en) |
WO (1) | WO2000050013A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002088246A1 (en) | 2001-04-26 | 2002-11-07 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Molded object having high pullulan content, process for producing the same, and use thereof |
WO2004043440A1 (en) * | 2002-11-12 | 2004-05-27 | Elan Pharma International Ltd. | Fast-disintegrating solid dosage forms being not friable and comprising pullulan |
WO2005105047A1 (en) * | 2004-04-30 | 2005-11-10 | Quantum Hi-Tech (Beijing) Research Institute | Orally disintegrating tablet and method of preparation |
WO2011036599A1 (en) * | 2009-09-28 | 2011-03-31 | Yeditepe Universitesi | A dissolvable film strip comprising natural components |
WO2011115969A2 (en) | 2010-03-16 | 2011-09-22 | Catalent Pharma Solutions, Llc | Process of manufacturing a lyophilized fast dissolving, muti-phasic dosage form |
EP2815743A1 (en) * | 2013-06-21 | 2014-12-24 | Sanovel Ilac Sanayi ve Ticaret A.S. | Ceftibuten formulations |
US11040015B2 (en) * | 2017-10-16 | 2021-06-22 | Mcmaster University | Method of long-term preservation of chemical and biological species using sugar glasses |
WO2021209945A1 (en) | 2020-04-16 | 2021-10-21 | Tavanta Therapeutics Hungary Incorporated | Methods and compositions for treating prostate cancer |
US11518764B2 (en) | 2018-02-06 | 2022-12-06 | Ontario Institute For Cancer Research (Oicr) | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction |
US11940444B2 (en) | 2013-11-08 | 2024-03-26 | Mcmaster University | Method of stabilizing molecules without refrigeration using water soluble polymers and applications thereof in performing chemical reactions |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017170763A1 (en) * | 2016-04-01 | 2017-10-05 | 株式会社クレハ | Disintegrable tablet and method for manufacturing same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991009591A1 (en) * | 1989-12-22 | 1991-07-11 | Mediventures, Inc. | Preparation of pharmaceutical and other matrix systems by solid-state dissolution |
US5064057A (en) * | 1987-04-30 | 1991-11-12 | Ajinomoto Co., Inc. | Support for anastomosing or connecting living organs |
JPH08291051A (en) * | 1995-04-17 | 1996-11-05 | Sato Seiyaku Kk | Method for producing rapidly soluble tablet and rapidly soluble tablet produced by the method |
WO1996040077A2 (en) * | 1995-06-07 | 1996-12-19 | Quadrant Holdings Cambridge Limited | Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby |
US5762961A (en) * | 1996-02-09 | 1998-06-09 | Quadrant Holdings Cambridge Ltd. | Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW527195B (en) * | 1997-10-09 | 2003-04-11 | Ssp Co Ltd | Fast-soluble solid pharmaceutical combinations |
GB9901819D0 (en) * | 1999-01-27 | 1999-03-17 | Scherer Corp R P | Pharmaceutical compositions |
-
1999
- 1999-02-22 GB GBGB9904049.5A patent/GB9904049D0/en not_active Ceased
-
2000
- 2000-02-22 AU AU26815/00A patent/AU2681500A/en not_active Abandoned
- 2000-02-22 EP EP00905188A patent/EP1156785A1/en not_active Withdrawn
- 2000-02-22 CA CA002363126A patent/CA2363126A1/en not_active Abandoned
- 2000-02-22 JP JP2000600625A patent/JP2002537322A/en active Pending
- 2000-02-22 WO PCT/GB2000/000630 patent/WO2000050013A1/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5064057A (en) * | 1987-04-30 | 1991-11-12 | Ajinomoto Co., Inc. | Support for anastomosing or connecting living organs |
WO1991009591A1 (en) * | 1989-12-22 | 1991-07-11 | Mediventures, Inc. | Preparation of pharmaceutical and other matrix systems by solid-state dissolution |
JPH08291051A (en) * | 1995-04-17 | 1996-11-05 | Sato Seiyaku Kk | Method for producing rapidly soluble tablet and rapidly soluble tablet produced by the method |
WO1996040077A2 (en) * | 1995-06-07 | 1996-12-19 | Quadrant Holdings Cambridge Limited | Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby |
US5762961A (en) * | 1996-02-09 | 1998-06-09 | Quadrant Holdings Cambridge Ltd. | Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof |
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, vol. 126, no. 6, 10 February 1997, Columbus, Ohio, US; abstract no. 79933, TATARA, MITSUTOSHI ET AL: "Method for manufacturing fast dissolving tablets" XP002138637 * |
DATABASE WPI Week 9718, Derwent World Patents Index; AN 1997-196011, "Rapidly-dissolving tablets production" * |
See also references of EP1156785A1 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7749538B2 (en) | 2001-04-26 | 2010-07-06 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Molded object having high pullulan content, process for the producing the same, and use thereof |
EP1398346A1 (en) * | 2001-04-26 | 2004-03-17 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Molded object having high pullulan content, process for producing the same, and use thereof |
EP1398346A4 (en) * | 2001-04-26 | 2004-08-25 | Hayashibara Biochem Lab | Molded object having high pullulan content, process for producing the same, and use thereof |
WO2002088246A1 (en) | 2001-04-26 | 2002-11-07 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Molded object having high pullulan content, process for producing the same, and use thereof |
WO2004043440A1 (en) * | 2002-11-12 | 2004-05-27 | Elan Pharma International Ltd. | Fast-disintegrating solid dosage forms being not friable and comprising pullulan |
US7815935B2 (en) | 2004-04-30 | 2010-10-19 | Quantum Hi-Tech (Beijing) Research Institute | Orally distintegrating formulation and process for preparing the same |
WO2005105047A1 (en) * | 2004-04-30 | 2005-11-10 | Quantum Hi-Tech (Beijing) Research Institute | Orally disintegrating tablet and method of preparation |
WO2011036599A1 (en) * | 2009-09-28 | 2011-03-31 | Yeditepe Universitesi | A dissolvable film strip comprising natural components |
WO2011115969A2 (en) | 2010-03-16 | 2011-09-22 | Catalent Pharma Solutions, Llc | Process of manufacturing a lyophilized fast dissolving, muti-phasic dosage form |
US10548839B2 (en) | 2010-03-16 | 2020-02-04 | Wei Tian | Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form |
EP2815743A1 (en) * | 2013-06-21 | 2014-12-24 | Sanovel Ilac Sanayi ve Ticaret A.S. | Ceftibuten formulations |
US11940444B2 (en) | 2013-11-08 | 2024-03-26 | Mcmaster University | Method of stabilizing molecules without refrigeration using water soluble polymers and applications thereof in performing chemical reactions |
US11040015B2 (en) * | 2017-10-16 | 2021-06-22 | Mcmaster University | Method of long-term preservation of chemical and biological species using sugar glasses |
US11518764B2 (en) | 2018-02-06 | 2022-12-06 | Ontario Institute For Cancer Research (Oicr) | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction |
WO2021209945A1 (en) | 2020-04-16 | 2021-10-21 | Tavanta Therapeutics Hungary Incorporated | Methods and compositions for treating prostate cancer |
Also Published As
Publication number | Publication date |
---|---|
AU2681500A (en) | 2000-09-14 |
JP2002537322A (en) | 2002-11-05 |
EP1156785A1 (en) | 2001-11-28 |
GB9904049D0 (en) | 1999-04-14 |
CA2363126A1 (en) | 2000-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0773781B1 (en) | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same | |
AU713599B2 (en) | Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby | |
US5762961A (en) | Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof | |
WO2000013680A2 (en) | Filamentous amorphous carbohydrate compositions and therapeutic delivery vehicles comprising them | |
US6893657B2 (en) | Solid dose delivery vehicle and methods of making same | |
KR100852015B1 (en) | Fast dispersing dosage forms free of gelatin | |
US20050186254A1 (en) | Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby | |
US5958455A (en) | Oral solid dosage forms, methods of making same and compositions thereof | |
WO2000050013A1 (en) | Rapidly-soluble compositions | |
JPS58113124A (en) | Solid formed article | |
BG100749A (en) | Rapidly dissolving oral dosage form | |
PL169807B1 (en) | Method of making dimeticon containing tablet for sucking | |
RU2177785C2 (en) | Solid delivery systems for controlled release of included molecules and method for their preparation | |
RU97103529A (en) | SOLID DELIVERY SYSTEMS FOR CONTROLLED RELEASE OF THE MOLECULES INCLUDED IN THEM AND METHODS OF THEIR PREPARATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000905188 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2363126 Country of ref document: CA Ref country code: CA Ref document number: 2363126 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 600625 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000905188 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09913814 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000905188 Country of ref document: EP |